FITT

Helsinn presents newly available data on vepafestinib at IASLC 2022 World Conference on Lung Cancer

Retrieved on: 
Monday, August 8, 2022
FITT, Lung cancer, Adenocarcinoma, Veni, vidi, vici, Respect, CNS, Diagnosis, Journal of Clinical Oncology, Growth, Cancer, Brain, PMID, Incidence, Memorial Sloan Kettering Cancer Center, Environment, NSCLC, Large-cell lung carcinoma, Corporation, WCLC, Partnership, Comparison, International Association, RET, Heart, MD, Non-Smokers' Rights Association, CMC, Conference, Margaret, Disease, Pharmaceutical industry, Medical imaging, Antibiotics, Patient

Lugano, Switzerland, August 8, 2022 - Helsinn Group (Helsinn), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, announces its participation in the upcoming IASLC 2022 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer, taking place from 6-9 August in Vienna, Austria.

Key Points: 
  • Lugano, Switzerland, August 8, 2022 - Helsinn Group (Helsinn), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets, announces its participation in the upcoming IASLC 2022 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer, taking place from 6-9 August in Vienna, Austria.
  • Dr. Sergio Cantoreggi, Helsinn Group Chief Scientific Officer and Head of R&D commented: We are excited to be presenting further preclinical data on vepafestinib at the IASLC 2022 World Conference on Lung Cancer.
  • These preclinical results support the continued investigation and development of vepafestinib in this disease space.
  • It is focused on improving the lives of cancer patients all over the world with a leading position in cancer supportive care and an innovative pipeline of cancer therapeutics.

Helsinn Establishes New R&D Hub in the U.S. to Support its Global Fully Integrated Targeted Therapy (FITT) Strategy

Retrieved on: 
Wednesday, May 25, 2022
Chemistry, Cancer, FITT, Â, Environment, Respect, Patient, CMC, GPX4, CCA, FGFR2, FGFR, HTU, Vomiting, Heart, RET, Therapy, Corporation, Transfection, Growth, Fine chemical, Pharmaceutical industry

Bringing this R&D expertise into HTU through this new hub complements the global R&D organization and is the next step in Helsinns strategy of creating a differentiated pipeline of highly innovative oncology assets and transforming Helsinn from a leading cancer supportive care company to a Fully Integrated Targeted Therapy company.

Key Points: 
  • Bringing this R&D expertise into HTU through this new hub complements the global R&D organization and is the next step in Helsinns strategy of creating a differentiated pipeline of highly innovative oncology assets and transforming Helsinn from a leading cancer supportive care company to a Fully Integrated Targeted Therapy company.
  • Over the next five years, Helsinn intends to continue investing approximately 35 percent of the revenues from its commercial engine of supportive care and cancer therapeutic products into targeted therapeutics R&D.
  • Dr. Giorgio Calderari, Helsinn Group CEO & Board Member, said: The implementation of Helsinns strategy continues at pace and we are excited to announce the enlarging of our global R&D organization by establishing a new hub in the U.S. as part of HTU.
  • Helsinn is a fully integrated, global biopharma company headquartered in Lugano, Switzerland.

Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer

Retrieved on: 
Thursday, May 19, 2022
Department, Medical Affairs Bureau, FITT, Fellow, Surgical oncology, Drug development, Research, Dermatology, Environment, Respect, Patient, Women's health, Therapy, University Hospital Heidelberg, Medical school, University, Secondary research, Organization, Heart, Medical research, Corporation, Cancer, Growth, Pharmaceutical industry, Medicine, Pharmacology

Lugano, Switzerland, May 19, 2022 Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, is pleased to announce the appointment of Dr Melanie Rolli as Group Chief Operating Officer (COO), effective June 1, 2022.

Key Points: 
  • Lugano, Switzerland, May 19, 2022 Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, is pleased to announce the appointment of Dr Melanie Rolli as Group Chief Operating Officer (COO), effective June 1, 2022.
  • Today, I am thrilled to announce that Dr Melanie Rolli will be joining Helsinn as Group Chief Operating Officer.
  • Dr Rolli is a highly experienced business leader having held several executive and non-executive roles in global pharmaceutical and biotech companies.
  • Dr Melanie Rolli, newly appointed Group Chief Operating Officer at Helsinn, commented: Helsinns mission is to improve the lives of cancer patients all over the world and this is fully aligned with what has driven me throughout my career.

Helsinn to present data at upcoming AMMF’s 2022 European Cholangiocarcinoma Conference

Retrieved on: 
Wednesday, May 11, 2022
CCA, Cholangiocarcinoma, Cancer, Bile, Radisson Blu Hotel Hamburg, Patient, FITT, Doctor of Philosophy, Alan, FGFR, Caregiver, Diagnosis, Environment, Incidence, Respect, MD, Corporation, AMMF, Observational study, London Stansted Airport, Master of Science, Research, Heart, Growth, Awareness, FGFR2, Pharmaceutical industry, Medical imaging

Helsinn will be present with a tabletop exhibit and will also contribute to the scientific exchange through the presentation of two scientific posters.

Key Points: 
  • Helsinn will be present with a tabletop exhibit and will also contribute to the scientific exchange through the presentation of two scientific posters.
  • AMMFs 2022 cholangiocarcinoma (CCA) conference will mark 20 years since the inception of AMMF UK Cholangiocarcinoma Charity.
  • The first poster is entitled Natural history of patients with advanced cholangiocarcinoma and FGFR2 gene fusions/rearrangements.
  • Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

AnaCardio exercises option to license a program in heart failure from Helsinn

Retrieved on: 
Thursday, February 3, 2022
Growth, Heart, Patient, Sale, Karolinska Institute, Hospital, Karolinska University Hospital, Corporation, Environment, Muscle tissue, Death, Cancer, Program, FITT, Respect, Heart failure, Cardiology, Pharmaceutical industry

Under the terms of the agreement, and upon payment of an undisclosed amount, AnaCardio has exercised its option and obtained an exclusive license from Helsinn for clinical development of the program in heart failure, with potential downstream revenue sharing upon the further license, sale or commercialization of the program.

Key Points: 
  • Under the terms of the agreement, and upon payment of an undisclosed amount, AnaCardio has exercised its option and obtained an exclusive license from Helsinn for clinical development of the program in heart failure, with potential downstream revenue sharing upon the further license, sale or commercialization of the program.
  • Benefitting from our deep expertise and the comprehensive pre-clinical and phase I data we have generated, Prof. Lund and AnaCardio are ideally placed to continue the clinical development of this program in heart failure.
  • This license agreement completes the transformation of AnaCardio into a fully operational, clinical-stage development company, and underscores our commitment to the heart failure community and to develop safe and efficacious treatments for this underserved patient group.
  • AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure.

Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes

Retrieved on: 
Thursday, January 13, 2022
Research, Applied science, FGFR2, ETH, FITT, CCA, Therapy, Environment, Health, Cancer, Respect, Corporation, P&G, Executive, The arts, Founder, Heart, Doctor of Philosophy, Director, Patient, CMC, Group, GPX4, Growth, Swiss Federal Institute of Aquatic Science and Technology, Health care, Master, City University, City, University of London, FGFR, CEO, Swiss Federal Institute of Technology, Business, University of Applied Sciences and Arts of Western Switzerland, RET, Vomiting, University, Board, Management, Fine chemical, Pharmaceutical industry, Novartis, Chemistry, EU

Gabriele Braglia, current Chairman and Founder, named Honorary Chairman

Key Points: 
  • Gabriele Braglia, current Chairman and Founder, named Honorary Chairman
    Lugano, Switzerland, January 13, 2021 - Helsinn Group (Helsinn), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, today announces the launch of its Fully Integrated Targeted Therapy (FITT) Strategy and Board and management changes.
  • Helsinns FITT strategy will focus on developing a differentiated pipeline of highly innovative oncology assets addressing unmet needs, transforming Helsinn from a leading cancer supportive care company to a fully integrated targeted therapy company.
  • A RET tyrosine kinase inhibitor currently in a Phase I/II trial that Helsinn believes has the potential for fast-track approval.
  • These combined changes will enable Helsinn to be fully focused on building out its targeted oncology pipeline.